Palvella Therapeutics, Inc. PVLA
152.93 USD +6.60 (+4.51%)
At closeNov 4, 2026, 7:41 AM EST
153.33 +0.40 +0.26%
Pre-market · Nov 4, 7:41 AM ET
142.89 Day range 153.86
72.23 52-week range 161.38
- YTD
- +46.11%
- 1 year
- +103.74%
Financial health
Altman Z-Score
35.54 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 5
- P/E 1
- P/B 1
Valuation
P/E -28.2×
FY 2020 5y median -0.6× FY 2025
P/S 0.0×
FY 2020 5y median 0.0× FY 2025
P/B 42.1×
FY 2020 5y median 0.3× FY 2025
P/FCF -47.1×
FY 2020 5y median -1.6× FY 2025
EV/EBITDA -31.2×
FY 2020 5y median 0.8× FY 2025
EV/Sales 0.0×
FY 2020 5y median 0.0× FY 2025
FCF Yield -2.1%
FY 2020 5y median -62.8% FY 2025
Profitability
Gross Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2020 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2020 5y median 0.0% FY 2025
ROE -149.1%
FY 2020 5y median -90.1% FY 2025
ROIC -79.7%
FY 2020 5y median -79.7% FY 2025
ROA -70.0%
FY 2020 5y median -29.8% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2020 FY 2025
Operating Income -173.9%
FY 2020 FY 2025
EPS (diluted) 52.6%
FY 2020 FY 2025
Free Cash Flow -130.7%
FY 2020 FY 2025
Financial Health
Current Ratio 5.2×
FY 2020 5y median 3.2× FY 2025
Quick Ratio 5.2×
FY 2020 5y median 3.2× FY 2025
Debt / Equity 0.0×
FY 2020 5y median 0.0× FY 2025
Net Debt / EBITDA 1.6×
FY 2020 5y median 1.6× FY 2025
Interest Coverage -6.6×
FY 2020 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2020 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2020 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31